Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway

US10588938B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Amato J. Giaccia · Stanford, US
• Mihalis Kariolis · South San Francisco, US
• Todd A. Aguilera · San Diego, US

Key dates

• Filing date: Oct 2, 2017
• Grant date: Mar 17, 2020
• Expiry date: Jan 31, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.